drugset
drugset / Trial / NCT06485245

Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060304 in Healthy and Elevated LDL-C Subjects

NCT06485245 ↗

Phase 1 Active not recruiting 80 enrolled Cascade Pharmaceuticals, Inc
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060304 in Healthy and Elevated LDL-C Subjects.

Timeline

Start
2025-04-22
Primary completion
2025-11-20
Completion
2026-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject CS060304 Unknown 0.2 mg Oral
Subject CS060304 Unknown 1 mg Oral
Subject CS060304 Unknown 2 mg Oral
Subject CS060304 Unknown 4 mg Oral
Subject CS060304 Unknown 5 mg Oral
Subject CS060304 Unknown 10 mg Oral
Subject CS060304 Unknown 20 mg Oral
Subject CS060304 Unknown 40 mg Oral

Indications

No indication recorded.